Legacy Pathways Can Outlive Their Original Logic
A familiar story: a device is built in one region, shipped across the country for sterilization, waits for processing, then moves again before reaching the market.
Terminal sterilization is the most expensive place to have problems. It sits at the end of the process, when the product is most valuable and closest to market, so any failure, delay, or yield loss lands at the costliest point in the chain.
Many pathways were built around decisions made years ago — lower volumes, different ownership or distribution, fewer options. Once a product is validated, those choices tend to become fixed, and transportation patterns, provider relationships, and modality decisions can persist long after they stop being optimal.
So it’s worth asking whether parts of your network now add friction and cost. Your supply chain should work for your business. We can help you map this out! Book a call →
What To Review In Your Sterilization Network
A sterilization network can add cost, delay, or risk in several ways. Map the full pathway and look for:
- Long processing times that inflate inventory costs
- Weather exposure that smarter planning or alternate capacity could reduce
- Finished goods tied up in transit instead of moving toward release
- Overreliance on one modality, provider, or geography
Transportation
Long routes add cost, time, and handling risk, especially when product crosses the country to be sterilized and then moves again before release.
Questions to ask:
- Where is the product manufactured, and where is it sterilized?
- What is the total timeline from departure to sterilizer to final destination?
- Are any lines moving “coast to coast” because of validations that no longer reflect supply chain reality?
Queue Time Before or After Sterilization
The cycle itself may be a small part of the timeline. Product can also wait on processing windows, documentation, release, or return shipment.
Questions to ask:
- How long does product wait before processing, and how long afterward before release?
- Is there significant variation in processing time? High variability can erase the value of a reasonable average.
- Are delays driven by capacity, documentation, transportation, or internal review?
Product-Level Issue vs. Portfolio-Level
An inefficient route for one low-volume line may be manageable next to the cost of re-validating. The real concern is when several lines share the same inefficient route or avoidable delay.
Questions to ask:
- Are multiple product lines traveling long distances for sterilization?
- Are product families on pathways designed for lower volumes, and would the problem look bigger mapped together?
Modality, Provider, or Geography Dependence
Overreliance becomes risk when capacity tightens, demand shifts, weather disrupts freight, or a provider runs short on availability.
Questions to ask:
- How much of the portfolio depends on a single modality, provider, or region?
- Could weather, freight, or regional disruption risks be reduced with smarter planning?
Modality and Operational Flexibility
EO, Gamma, and E-Beam create different supply chain realities. EO can mean longer cycles and aeration time; Gamma depends on source capacity. For compatible products, E-Beam offers fast processing, flexible scheduling, and less dependence on constrained pathways.
Questions to ask:
- Does the current modality still make sense for the product?
- Could another modality cut transit time, queue time, or inventory burden?
- Are there products worth evaluating for E-Beam or X-ray?
Legacy Validation Paths
Many pathways were set at first validation. Those choices may still be right, or they may reflect outdated assumptions about volume, geography, provider access, or modality options.
Questions to ask:
- When was the current pathway established, and has the manufacturing location changed since?
- Have volumes grown or demand shifted, and are there newer options that weren’t practical before?
What A Sterilization Supply Chain Analysis Can Show
A custom analysis can pinpoint where your network adds time, cost, or risk, and flag products worth a closer look — whether that means E-Beam feasibility testing, dose mapping, material compatibility review, or a broader network discussion.
The goal is to show where to look first, then help quality, regulatory, operations, and leadership decide whether a more efficient path is worth pursuing.
We can help you map this out! Book a call →
Additional Articles We Think You Might Like
Have a question? Speak with a sterilization expert today, at your own convenience.
